Note: Descriptions are shown in the official language in which they were submitted.
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
METHODS FOR TREATING SARCOPENIA AND FRAILTY
FIELD OF THE INVENTION
The present invention relates to the use of neuregulin-1 (NRG1) and/or vitamin
B12 for
maintaining or increasing muscle function and/or muscle mass in ageing
subjects. In
particular, the invention relates to the use of NRG1 and/or vitamin B12 for
treating sarcopenia
or physical frailty.
BACKGROUND TO THE INVENTION
Age-related loss of muscle function and mass occurs inevitably in all
individuals, however its
progression depends on a range of genetic and environmental factors, such as
physical
activity and nutritional intake.
In some subjects, the effect of ageing on muscle may progress to a state of
morbidity, specific
conditions of which include sarcopenia and frailty. Sarcopenia is defined as
occurring at the
point at which the age-related loss of muscle function and mass becomes
debilitating and
impacts on quality of life (Sayer, A.A. et al. (2013) Age Ageing 42: 145-150).
In contrast, frailty
is a classification of age-related muscle dysfunction which relies on muscle
strength and
functionality, but not muscle mass (Morley, J.E. et al. (2013) J. Am. Med.
Dir. Assoc. 14: 392-
397).
Sarcopenia and frailty are multi-factorial syndromes which associate with
pathophysiological
changes, such as impaired neuro-muscular transition, altered
excitation/contraction coupling,
impaired regenerative capacity linked to stem cell exhaustion, defects of
mitochondrial and
energy metabolism in myofibers, and marbling of skeletal muscle with fat and
fibrosis (Ali, S.
et al. (2014) Gerontology 60: 294-305). The aetiology of these syndromes is
therefore complex
and poorly understood, but low physical activity, hormonal decline in anabolic
hormones (e.g.
androgens and IGF-1), and malnutrition and/or nutritional deficiencies play an
important role
(Mithal, A. et al. (2013) Osteoporos. Int. 24: 1555-1566).
Sarcopenia is becoming a major health concern in developed countries, where
lessened
physical activity with age and increased longevity are particularly prevalent.
In severe cases,
sarcopenia may result in a person losing their ability to live independently.
In addition,
sarcopenia is a predictor of wider-ranging disability in population-based
studies, and has been
linked to poor balance, gait speed, prevalence of falls and fractures.
Reduced physical activity is thought to increase the likelihood of sarcopenia
and therefore
increased exercise will likely be beneficial in combatting the condition.
Indeed, resistance
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
exercise is associated with increased synthesis of proteins in skeletal
muscle. However,
exercise as a treatment often suffers from poor patient compliance.
There are currently no pharmacological agents approved for the treatment of
sarcopenia. A
number of growth hormones have been studied in this context, however these
have shown
little effect. In addition, anabolic steroids may increase muscle mass and
strength, but are
associated with a number of side effects, such as increased risk of prostate
cancer. Moreover,
existing pharmacological and nutritional approaches are mainly directed at
targeting muscle
anabolism and do not adequately address the neuromuscular defects associated
with the
condition.
Accordingly there remains a significant need for methods of maintaining or
increasing muscle
function and mass in ageing subjects. In particular, there is a need for
methods of treating
sarcopenia and frailty.
SUMMARY OF THE INVENTION
The role of neuregulin-1 (NRG1) in both nerve and muscle development and
maintenance has
been studied for some time. For example, NRG1 is known to be produced by
muscle and to
be essential for myogenic differentiation. It has also been shown that NRG1 is
involved in
signalling cascades for contraction and glucose metabolism. However, no link
has been
previously made between NRG1 levels and the age of an individual.
The present inventors have surprisingly found that expression of NRG1
decreases with age.
Having established the link between age and NRG1, the inventors proceeded to
demonstrate
that increasing NRG1 levels in ageing animal models reversed the wasting
effect of age on
muscle.
In summary, the inventors have unexpectedly found that increasing levels of
NRG1 in ageing
subjects is clinically applicable to the treatment of age-related decline in
muscle function and
mass, and therefore provides a route to the treatment of age-related
conditions such as
sarcopenia and frailty.
In addition, the inventors have unexpectedly found that increasing levels of
vitamin B12 in
ageing subjects is clinically applicable to the treatment of age-related
decline in muscle
function and mass, and therefore provides a route to the treatment of age-
related conditions
such as sarcopenia and frailty.
In particular, the inventors have surprisingly found that different vitamin
B12 isoforms have
particular effects on different systems and pathways. Accordingly, particular
vitamin B12
2
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
isoforms, or combinations of vitamin B12 isoforms, can be chosen to provide
particularly
beneficial effects in a subject.
Accordingly, in one aspect, the invention provides neuregulin-1 (NRG1) or a
fragment thereof
for use in maintaining or increasing muscle function and/or mass in an ageing
subject, and/or
substantially preventing or reducing muscle wasting in an ageing subject.
In another aspect, the invention provides vitamin B12 for use in maintaining
or increasing
muscle function and/or mass in an ageing subject, and/or substantially
preventing or reducing
muscle wasting in an ageing subject.
The ageing subject may, for example, be a human subject over the age of 30,
35, 40, 45, 50,
55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 years old.
Preferably, the muscle is skeletal muscle.
In one embodiment, the NRG1 or fragment thereof or the vitamin B12 maintains
or increases
muscle mass.
In another embodiment, the NRG1 or fragment thereof substantially prevents or
reduces a
reduction in muscle mass. The prevention or reduction in muscle mass may be in
comparison
to the reduction in muscle mass that would be expected in the absence of the
NRG1 or
fragment thereof of the invention.
In another embodiment, the vitamin B12 substantially prevents or reduces a
reduction in
muscle mass. The prevention or reduction in muscle mass may be in comparison
to the
reduction in muscle mass that would be expected in the absence of the vitamin
B12 of the
invention.
In another aspect, the invention provides neuregulin-1 (NRG1) or a fragment
thereof or vitamin
B12 for use in treating sarcopenia or frailty.
The NRG1 or fragment thereof for use according to the invention may be in a
combined
preparation with vitamin B12 for simultaneous, combined, sequential or
separate
administration to a subject.
In one embodiment, the NRG1 or fragment thereof of the invention is a NRG1
type I, II, Ill, IV,
V or VI isoform.
Preferably, the NRG1 or fragment thereof of the invention is a NRG1 type I
isoform.
3
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
In another embodiment, the NRG1 or fragment thereof of the invention is a NRG1
HRG-alpha,
HRG-beta or HRG-gamma isoform
Preferably, the NRG1 or fragment thereof of the invention is a NRG1 HRG-beta
isoform.
In one embodiment, the NRG1 or fragment thereof of the invention is a NRG1 HRG-
beta1
isoform. In another embodiment, the NRG1 or fragment thereof of the invention
is a NRG1
HRG-beta2 isoform. In another embodiment, the NRG1 or fragment thereof of the
invention is
a NRG1 HRG-beta3 isoform.
In one embodiment, the NRG1 fragment of the invention comprises an NRG1 EGF
domain.
In one embodiment, the NRG1 or fragment thereof of the invention comprises an
amino acid
sequence selected from the group consisting of:
(a) an amino acid sequence that has at least 60% identity to SEQ ID NO: 1
or
5;
(b) an amino acid sequence that has at least 60% identity to SEQ ID NO: 2,
3,
4 or 6; and
(c) an amino acid sequence that has at least 60% identity to SEQ ID NO: 7
or
8, preferably SEQ ID NO: 7;
Preferably, the NRG1 or fragment thereof provides for maintaining or
increasing muscle
function and/or mass in an ageing subject and/or substantially preventing or
reducing muscle
wasting in an ageing subject. Preferably, the NRG1 or fragment thereof
substantially retains
the natural function of the protein represented by SEQ ID NO: 7.
In another embodiment, the NRG1 or fragment thereof of the invention comprises
an amino
acid sequence that has at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or
100%
identity to SEQ ID NO: 1 or 5. Preferably, the NRG1 or fragment thereof
provides for
maintaining or increasing muscle function and/or mass in an ageing subject
and/or
substantially preventing or reducing muscle wasting in an ageing subject.
Preferably, the
NRG1 or fragment thereof substantially retains the natural function of the
protein represented
by SEQ ID NO: 7.
In another embodiment, the NRG1 or fragment thereof of the invention comprises
an amino
acid sequence that has at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or
100%
identity to SEQ ID NO: 2, 3, 4 or 6. Preferably, the NRG1 or fragment thereof
provides for
maintaining or increasing muscle function and/or mass in an ageing subject
and/or
4
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
substantially preventing or reducing muscle wasting in an ageing subject.
Preferably, the
NRG1 or fragment thereof substantially retains the natural function of the
protein represented
by SEQ ID NO: 7.
In another embodiment, the NRG1 or fragment thereof of the invention comprises
an amino
acid sequence that has at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or
100%
identity to SEQ ID NO: 7 or 8, preferably SEQ ID NO: 7. Preferably, the NRG1
or fragment
thereof provides for maintaining or increasing muscle function and/or mass in
an ageing
subject and/or substantially preventing or reducing muscle wasting in an
ageing subject.
Preferably, the NRG1 or fragment thereof substantially retains the natural
function of the
protein represented by SEQ ID NO: 7.
Preferably, the NRG1 or fragment thereof of the invention provides a similar
or increased effect
of:
(a) maintaining or increasing muscle function and/or mass in an
ageing
subject;
(b) preventing or reducing muscle wasting in an ageing subject; and/or
(c) treating sarcopenia or frailty,
compared to the protein of SEQ ID NO: 7.
In another aspect, the invention provides a polypeptide comprising a NRG1 EGF
domain for
use in maintaining or increasing muscle function and/or mass in an ageing
subject, and/or
substantially preventing or reducing muscle wasting in an ageing subject.
In one embodiment, the NRG1 or fragment thereof maintains or increases muscle
mass.
In another aspect, the invention provides a polypeptide comprising a NRG1 EGF
domain for
use in treating sarcopenia or frailty.
The use may be as described herein.
In one embodiment, the vitamin B12 may be adenosylcobalamin and/or
methylcobalamin.
In another embodiment, the vitamin B12 may be hydroxocobalamin and/or
cyanocobalamin
which can be converted into methylcobalamin and/or adenosylcobalamin.
In one aspect the present invention provides adenosylcobalamin for use in
maintaining or
increasing muscle function and/or muscle mass in an ageing subject. In a
particular
5
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
embodiment the present invention provides adenosylcobalamin for use in
increasing muscle
fiber size in an ageing subject.
In one aspect the present invention provides methylcobalamin for use in
substantially
preventing or reducing muscle wasting in an ageing subject. In a particular
embodiment, the
present invention provides methylcobalamin for use in substantially preventing
or reducing
muscle atrophy in an ageing subject.
In one embodiment the present invention provides a combination of
adenosylcobalamin and
methylcobalamin for use maintaining or increasing muscle function and/or mass
and reducing
muscle atrophy in an ageing subject. In a particular embodiment the present
invention
provides a combination of adenosylcobalamin and methylcobalamin for use
increasing muscle
fiber size and substantially preventing or reducing muscle atrophy in an
ageing subject.
The vitamin B12 may be administered by oral, parental, sub-lingual, sub-
cutaneous,
transdermal or intra-nasal administration.
The vitamin B12 may be administered as an oral vitamin B12 supplement or a
probiotic
supplement comprising vitamin B12 producing bacteria. The vitamin B12 may, for
example,
be in the form of a nutritional composition or supplement, or a diet product.
In one embodiment, the subject may have previously been determined to be
vitamin B12
deficient.
In another aspect, the invention provides a method of maintaining or
increasing muscle
function and/or mass in an ageing subject comprising administering the
neuregulin-1 (NRG1)
or a fragment thereof or vitamin B12 of the invention to a subject in need
thereof.
In one embodiment, the NRG1 or fragment thereof or vitamin B12 or vitamin B12
maintains or
increases muscle mass.
In another embodiment, the NRG1 or fragment thereof or vitamin B12
substantially prevents
or reduces a reduction in muscle mass.
In another aspect, the invention provides a method of substantially preventing
or reducing
muscle wasting in an ageing subject comprising administering the neuregulin-1
(NRG1) or a
fragment thereof or vitamin B12 of the invention to a subject in need thereof.
The vitamin B12 may maintain or increase muscle function and/or mass, and/or
substantially
prevent or reduce muscle wasting in a manner as described herein.
6
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
In another aspect, the invention provides a method of treating sarcopenia or
frailty comprising
administering neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 of the
invention to a
subject in need thereof.
Preferably, the muscle is skeletal muscle.
In another aspect, the invention provides use of the neuregulin-1 (NRG1) or a
fragment thereof
or vitamin B12 of the invention for the manufacture of a medicament for:
(a) maintaining or increasing muscle function and/or mass in an ageing
subject;
(b) substantially preventing or reducing muscle wasting in an ageing
subject;
and/or
(c) treating sarcopenia or frailty.
In one embodiment, the medicament maintains or increases muscle mass.
In another embodiment, the medicament substantially prevents or reduces a
reduction in
muscle mass.
In another aspect, the invention provides a combined preparation of neuregulin-
1 (NRG1) or
a fragment thereof of the invention and vitamin B12, wherein the NRG1 or
fragment thereof
and vitamin B12 are for simultaneous, combined, sequential or separate
administration to a
subject.
The vitamin B12 of the combined preparation may, for example, be in the form
of a nutritional
composition or supplement, or a diet product. The NRG1 of fragments thereof
may, for
example, be in a form suitable for parenteral administration (e.g. sub-
cutaneous, intravenous
or intramuscular injection)
In another aspect, the invention provides a method of screening for an agent
capable of
increasing neuregulin-1 (NRG1) levels in a subject comprising the steps:
(a) contacting a population of cells with a candidate agent;
(b) determining the level of NRG1 in the population of cells; and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level in
a
control population of cells which has not been contacted with the candidate
agent.
7
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
The candidate agent may, for example, be a pharmaceutical agent or nutritional
supplement.
Preferably, the candidate agent is a nutritional supplement.
In one embodiment, the candidate agent is comprised in a library of candidate
agents.
In another aspect, the invention provides an agent for increasing neuregulin-1
(NRG1) levels
in a subject, preferably wherein the agent has been identified by the method
of screening of
the invention.
Preferably, the agent is a nutritional supplement.
The agent may be in a combined preparation with vitamin B12, wherein the agent
and vitamin
B12 are for simultaneous, combined, sequential or separate administration to a
subject.
In another aspect, the invention provides the agent of the invention for use
in:
(a) maintaining or increasing muscle function and/or mass in an ageing
subject;
(b) substantially preventing or reducing muscle wasting in an ageing
subject;
and/or
(c) treating sarcopenia or frailty.
Preferably, the muscle is skeletal muscle.
In another aspect, the invention provides a method of diagnosing sarcopenia or
frailty
comprising the steps:
(a) providing a biological sample isolated from a subject;
(b) determining the level of neuregulin-1 (NRG1) in the biological sample;
and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level
determined from one or more control samples or reference levels.
In another aspect, the invention provides a diet product for use in
maintaining or increasing
muscle function and/or mass in an ageing subject, and/or substantially
preventing or reducing
muscle wasting in an ageing subject.
In another aspect, the invention provides a diet product for use in treating
sarcopenia or frailty.
8
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Preferably, the diet product of the invention is for use in a subject that has
been diagnosed as
having sarcopenia or frailty, or being at risk of developing sarcopenia or
frailty using a method
of the invention.
In one embodiment, the diet product of the invention is for use in a vitamin
B12 deficient
subject.
In another aspect, the neuregulin-1 (NRG1) or fragment thereof; vitamin B12;
agent; or diet
product of the invention may be used in combination with an exercise regime to
maintain or
increase muscle function and/or mass.
In another aspect, the neuregulin-1 (NRG1) or fragment thereof; vitamin B12;
agent; or diet
product of the invention may be used in combination with other pharmaceutical
compositions,
including selective androgen receptor modulators (SARMs), such as ostarine or
myostatin
blockers (e.g. myostatin antibodies, activin receptor antibodies and activin
receptor-Fc), such
as LY2495655 or Bimagrumab, or beta2 receptor agonists such as formoterol, or
ghrelin
receptor agonists such as anamorelin, or anabolic catabolic transforming
agents (ACTA), such
as MT-102.
DESCRIPTION OF THE DRAWINGS
Figure 1
Circulating levels of neuregulin-1 (NRG1) decrease with age in rats.
Neuregulin-1 (NRG1) levels were measured in serum from rats aged 8 months, 18
months or
24 months using the slow off-rate DNA aptamer detection and quantification was
performed
after median-normalisation of Relative Fluorescence Units (RFU). 10 animals
per group were
analysed. ** = p-value <0.01.
Figure 2
Neuregulin-1 (NRG1) protects neuromuscular junctions from damage in vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (2.5 pM) and riluzole
was used as
a positive control for preserving neuromuscular junctions from Ab-induced
damage. The effect
of neuregulin-1 (NRG1) on Ab-induced damage was evaluated by measuring the
neuromuscular junction (NMJ) size. All values are from 6 wells per group and
are shown as a
percent of the control condition (CTL). ** = p-value < 0.01; ' = p-value
<0.001.
9
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Figure 3
Neuregulin-1 (NRG1) protects skeletal muscle from age-induced atrophy.
Pre-sarcopenic rats aged 16 months were treated for 5 months with either
neuregulin-1
(NRG1) or saline. NRG1 was injected sub-cutaneously at 1 pg/kg body weight 3
times per
week. Hind-limb skeletal muscle mass was then evaluated and compared to a
group of adult
healthy rats (8 months old at the start of the experiment) injected with
saline control. * = p-
value < 0.05 ; ** = p-value < 0.01.
Figures 4A-C
Vitamin B12 protects neuromuscular junctions from damage in vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (2.5 pM) and riluzole
was used as
a positive control for preserving neuromuscular junctions from Ab-induced
damage. The effect
of methylcobalamin (MeCb1) and adenosylcobalamin (AdenoCb1) on Ab-induced
damage was
evaluated by measuring: Figure 4A the neuromuscular junction (NMJ) size,
Figure 4B the
neuromuscular junction number and Figure 40 the neurite network length. All
values are from
6 wells per group and are shown as a percent of the control condition (CTL).
** = p-value <
0.01; ' = p-value <0.001.
Figures 5A and 5B
Neuregulin-1 (NRG1) and vitamin B12 have additive effects on neuromuscular
junction
protection in vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (10 pM) and riluzole was
used as a
positive control for preserving neuromuscular junctions from Ab-induced
damage. The effect
of neuregulin-1 (NRG1) and/or adenosylcobalamin (AdoCb1) on Ab-induced damage
was
evaluated by measuring the neuromuscular junction (NMJ) number (A) and size
(B). All values
are from 6 wells per group and are shown as a percent of the control condition
(CTL). ** = p-
value <0.01; ' = p-value <0.001.
Figures 6A and 6B
Adenosylcobalamin induces an increase in muscle fiber size in aged rats.
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Old sarcopenic rats were treated with methyl-cobalamin (MeObi) in Figure 6A or
adenosyl-
cobalamin (AdoObi) in Figure 6B for 5 months between 18 and 23 months of age,
and
compared to age matched sarcopenic controls (old CTL) or young adult healthy
controls
(adult). Tibialis anterior muscle was dissected out, sectioned and
immunostained for fibers.
Fiber size distribution for representative type 2A is shown. All values are
from 9 animals per
group.
Figure 7
Methylcobalamin protects from muscle atrophy
Human myoblasts were induced to form myotubes in the presence of the atrophic
factor TNFa
and different forms of vitamin B12 on a 2D+ micro-pattern inducing myotube
alignment. IGF
is used as a positive control to prevent TNFa-induced atrophy. Fusion index
was calculated
as the percentage of nuclei inside myotubes (i.e containing 2 nuclei) over the
total number
of nuclei. Values are from 3 wells per group and are shown as a percent of the
control condition
(CTL). ** = p-value < 0.01 and *** = p-value < 0.001 compared to CTL
condition. ## = p-value
<0.01 compared to TNFa condition.
Figures 8A-C
Adenosylcobalamin specifically reverses gene expression signatures associated
with
sarcopenia while methylcobalamin affects different gene expression signatures
in
skeletal muscle.
Old sarcopenic rats were treated with adenoysyl-cobalamin (AdoObi) or methyl-
cobalamin
(MeObi) for 5 months between 18 and 23 months of age, and compared to age
matched
sarcopenic controls (old CTL) or young adult healthy controls (adult).
Tibialis anterior muscle
was dissected out for RNA extraction and micro-array analysis. GSEA gene
enrichments for
top regulated pathways in Figure 8A old controls vs adult, Figure 8B old
treated with adenosyl-
cobalamin vs old controls and Figure 80 old treated with methyl-cobalamin
versus old controls
are shown.
DETAILED DESCRIPTION OF THE INVENTION
Various preferred features and embodiments of the present invention will now
be described
by way of non-limiting examples.
The practice of the present invention will employ, unless otherwise indicated,
conventional
techniques of chemistry, biochemistry, molecular biology, microbiology and
immunology,
which are within the capabilities of a person of ordinary skill in the art.
Such techniques are
11
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
explained in the literature. See, for example, Sambrook, J., Fritsch, E.F. and
Maniatis, T.
(1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor
Laboratory
Press; Ausubel, F.M. et al. (1995 and periodic supplements) Current Protocols
in Molecular
Biology, Ch. 9, 13 and 16, John Wiley & Sons; Roe, B., Crabtree, J. and Kahn,
A. (1996) DNA
Isolation and Sequencing: Essential Techniques, John Wiley & Sons; Polak, J.M.
and McGee,
J.O'D. (1990) In Situ Hybridization: Principles and Practice, Oxford
University Press; Gait, M.J.
(1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and LiIley,
D.M. and
Dahlberg, J.E. (1992) Methods in Enzymology: DNA Structures Part A: Synthesis
and Physical
Analysis of DNA, Academic Press. Each of these general texts is herein
incorporated by
reference.
Neuregulin
In one aspect, the invention provides neuregulin-1 (NRG1) or a fragment
thereof for use in
maintaining or increasing muscle function and/or mass in an ageing subject,
and/or
substantially preventing or reducing muscle wasting in an ageing
subject.Neuregulins are a
family of soluble and transmembrane growth factors characterised by an EGF-
like domain.
The neuregulins are mainly expressed by cells of endothelial, neuronal and
mesenchymal
origin and are involved in a diversity of biological functions such as
proliferation, survival or
migration.
The neuregulin-1 (NRG1) gene produces six known NRG1 isoforms by alternative
splicing,
which are termed the type I, II, Ill, IV, V and VI isoforms. Each isoform
contains the EGF-like
domain that is necessary for receptor activation. The expression of the
different isoforms is
spatially and temporally regulated, suggesting that each isoform may have a
specific function.
All isoforms induce intracellular signaling cascades by acting on specific
combinations of the
ErbB2, ErbB3 and ErbB4 receptors depending on the isoform (Yarden, Y. et al.
(2001) Nat.
Rev. Mol. Cell Biol. 2: 127-137).
In one embodiment, the NRG1 or fragment thereof of the invention is human NRG1
or
fragment thereof.
In one embodiment, the NRG1 or fragment thereof of the invention is a NRG1
type I, II, Ill, IV,
V or VI isoform.
Preferably, the NRG1 or fragment thereof of the invention is a NRG1 type I
isoform. The NRG1
type I isoform may alternatively be known as heregulin (HRG), NEU
differentiation factor
(NDF) and acetylcholine receptor inducing activity (ARIA).
12
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
An example amino acid sequence of the NRG1 HRG-alpha isoform is:
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSS
(SEQ ID NO: 1)
An example amino acid sequence of the NRG1 HRG-beta1 isoform is:
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEF
TGDRCQNYVMASFYKHLGIEFMEAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLR
SERNNTMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSW
SNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSA
MTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFS
SFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSS
NSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV
(SEQ ID NO: 2)
An example amino acid sequence of the NRG1 HRG-beta2 isoform is:
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEF
TGDRCQNYVMASFYKAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNTMN
IANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESI
LSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMS
PVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAH
DSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETED
ERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV
(SEQ ID NO: 3)
An example amino acid sequence of the NRG1 HRG-beta3 isoform is:
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEF
TGDRCQNYVMASFYSTSTPFLSLPE
(SEQ ID NO: 4)
An example amino acid sequence of the NRG1 HRG-gamma isoform is:
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCK
(SEQ ID NO: 5)
A further example amino acid sequence of the NRG1 HRG-beta isoform is:
13
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFK
NGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTE
GAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEF
TGDRCQNYVMASFYKHLGIEFMEQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNN
MMNIANGPHHPN
(SEQ ID NO: 6)
An example amino acid sequence of the EGF domain of NRG1 is:
SHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKHLGIEF
(SEQ ID NO: 7; NRG1 beta)
A further example amino acid sequence of the EGF domain is:
HLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARC
(SEQ ID NO: 8; NRG1 alpha)
The NRG1 fragment of the invention is a portion of the full-length polypeptide
that maintains
the desired function, preferably providing for maintaining or increasing
muscle function and/or
mass in an ageing subject and/or substantially preventing or reducing muscle
wasting in an
ageing subject, for example the fragment may substantially retain the natural
function of the
protein represented by SEQ ID NO: 7. The fragment may substantially retain the
natural
function of the full-length NRG1.
Preferably, the NRG1 fragment of the invention provides a similar or increased
effect of:
(a) maintaining or increasing muscle function and/or mass in an ageing
subject;
(b) preventing or reducing muscle wasting in an ageing subject; and/or
(c) treating sarcopenia or frailty,
compared to the protein of SEQ ID NO: 7.
The NRG1 fragment of the invention may be a polypeptide comprising a NRG1 EGF
domain,
for example an amino acid sequence that has at least 60%, 70%, 80%, 90%, 95%,
96%, 97%,
98%, 99% or 100% identity to SEQ ID NO: 7 or 8, preferably SEQ ID NO: 7,
preferably wherein
the NRG1 fragment substantially retains the natural function of the protein
represented by
SEQ ID NO: 7.
In the peripheral nervous system, NRG1 plays a key role in the myelination
process both
during development and following injury. The myelin lipid-rich sheath
surrounding axons
14
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
allows proper electric signal conduction and velocity, and is produced by the
Schwann cells
juxtaposed to axons. During the early postnatal development Schwann cells are
induced to
myelinate upon exogenous cues, one of them being NRG1. The importance of NRG1
for
myelination has been shown using mutant mice lacking NRG1 in which nerves
display a hypo-
myelinated phenotype (Gambarotta, G. et al. (2013) Int. Rev. Neurobiol. 108:
223-256).
Similarly, nerve regeneration and re-myelination is incomplete in the absence
of neuregulin-1
but is enhanced following neuregulin-1 overexpression or injection
(Gambarotta, G. et al.
(2013) Int. Rev. Neurobiol. 108: 223-256; Stassart, R.M. et al. (2013) Nat.
Neurosci. 16: 48-
54; Fricker, F.R. et al. (2011) J. Neurosci. 31: 3225-3233).
At the skeletal muscle level NRG1, has been linked to formation and
maintenance of
neuromuscular junctions, highly specialised structures allowing the
transmission of the electric
impulse from the nerve to the muscle for contraction. The vertebrate
neuromuscular junction
is constituted of a presynaptic nerve terminal provided by a motoneuron, a
postsynaptic
muscular part made of aggregates of acetylcholine receptors and a terminal
Schwann cell.
During development, the expression of acetylcholine receptors is induced by
NRG1 and their
aggregation by neuronal agrin. NRG1 is also thought to be important for
neuromuscular
junctions maintenance during adulthood. In one study, it was shown that
deletion of ErbB2
and ErbB4 in mouse skeletal muscle did not affect neuromuscular junction
formation,
suggesting that NRG1 could act on the neuromuscular junctions indirectly via
Schwann cells.
The NRG1 or fragment thereof of the invention may be administered to a subject
in the form
of a protein. Suitable routes of administration include sub-cutaneous,
intravenous and
intramuscular injection.
The NRG1 or fragment thereof of the invention may be administered to a subject
via gene
therapy. For example, a polynucleotide encoding the NRG1 or fragment thereof
of the
invention may be introduced into a target cell of the subject. A number of
suitable vectors for
the delivery of a polynucleotide encoding the NRG1 or fragment thereof of the
invention are
available, including viral vectors, such as retroviral, lentiviral, adenoviral
and adeno-
associated viral vectors.
Vitamin B12
In one aspect, the invention provides vitamin B12 for use in maintaining or
increasing muscle
function and/or mass in an ageing subject, and/or substantially preventing or
reducing muscle
wasting in an ageing subject.
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Vitamin B12 (also known as cobalamine) is a class of cobalt-containing
hydrosoluble vitamins
which cannot be synthesised by the human body and must therefore be acquired
from food or
synthesised by the gut microbiota.
The vitamin B12 class may refer to several chemical forms of vitamin B12,
depending on the
upper axial ligand of the cobalt ion. These are:
Cyanocobalamin (R = -ON)
Hydroxocobalamin (R = -OH)
Methylcobalamin (R = -CH3), and
Adenosylcobalamin (R = - 5'-deoxyadenosyl).
H2N,10
N
-
s CH3 C f I
o
H-C,%*."
Ni H 2
t 4
1
H2N N N
i3
0
0
C
411
C
P\
0 OHO
0
iC)
16
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
The vitamin B12 pool in the human body is composed of several forms:
cyanocobalamin,
which is inactive and requires conversion for activity, and methylcobalamin
and
adenosylcobalamin, which are the metabolically active forms of vitamin B12.
Two enzymes are known to rely on vitamin B12 as a cofactor: methionine
synthase and
methylmalonylCoA mutase. Methionine synthase is a cytoplasmic enzyme relying
on methyl-
cobalamine to convert homocysteine to methionine. It thereby plays a critical
role in providing
S-adenosylmethionine (SAM) as a methylation donor and preventing the toxic
accumulation
of homocysteine. Low SAM levels and high homocysteine levels observed upon
severe
vitamin B12 deficiency impair myelination of peripheral nerves and the spinal
cord. Methionine
synthase also catalyses the activation of 5-methyl-tetrahydrofolate into the
bioactive
tetrahydrofolate, which is required for 1-carbon metabolism and DNA synthesis,
and thus for
efficient red blood cell proliferation. MethylmalonylCoA mutase is a
mitochondrial enzyme
relying on adenosyl-cobalamine to convert methyl-malonylCoA to succinylCoA,
which
subsequently enters the TCA cycle. It is implicated in the degradation of
branched-chain amino
acids and odd-chain length fatty acids, and is essential during embryonic life
to control
neurological development, but is not vital in adult life
The vitamin B12 of the invention may be in the form of, for example, vitamin
B12 itself, the
semi-synthetic derivative cyanocobalamin, hydroxocobalamin, methylcobalamin
and/or
adenosylcobalamin.
In one embodiment, the vitamin B12 for use according to the present invention
is not
administered in combination with NRG1 or a fragment thereof as described
herein.
The vitamin B12 of the invention may be in the form of, for example,
adenosylcobalamin,
methylcobalamin, cyanocobalamin and/or hydroxocobalamin.
In one embodiment, the vitamin B12 may be adenosylcobalamin and/or
methylcobalamin. In
a preferred embodiment, the vitamin B12 may be adenosylcobalamin.
In one embodiment the adenosylcobalamin maintains or increases muscle mass,
for example
in one embodiment, the adenosylcobalamin increases muscle fibre size.
In one aspect the present invention provides the use of adenosylcobalamin for
increasing
maintaining or increasing muscle mass in an ageing subject.
In another aspect the present invention provides a method for maintaining or
increasing
muscle mass in an ageing subject, which comprises the step of administering
adenosylcobalamin to an ageing subject in need thereof.
17
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
In one aspect the present invention provides the use of adenosylcobalamin in
the manufacture
of a medicament for maintaining or increasing muscle mass in an ageing
subject.
In some embodiments described herein, the adenosylcobalamin maintains or
increases
muscle size by maintaining or increasing muscle fiber size.
In one embodiment the methylcobalamin substantially prevents or reduces muscle
wasting.
As used herein, muscle wasting may be synonymous with 'muscle atrophy' and is
used to
refer to a decrease in the mass of muscle. In one embodiment reducing muscle
atrophy may
therefore be synonymous with maintaining muscle mass.
In one aspect the present invention provides the use of methylcobalamin for
substantially
preventing or reducing muscle atrophy in an ageing subject.
In another aspect the present invention provides a method for substantially
preventing or
reducing muscle atrophy in an ageing subject, which comprises the step of
administering
methylcobalamin to an ageing subject in need thereof.
In one aspect the present invention provides the use of methylcobalamin in the
manufacture
of a medicament for substantially preventing or reducing muscle atrophy in an
ageing subject.
In one embodiment the present invention provides a combination of
adenosylcobalamin and
methylcobalamin for use in maintaining or increasing muscle mass and
substantially
preventing or reducing muscle wasting in an ageing subject.
The vitamin B12 of the invention may be administered to a subject by any
suitable route, for
example orally, intranasally, intravenously, parentally, sub-linguially, sub-
cutaneously,
transdermallyor intramuscularly.
In another aspect the present invention provides a method of treating
sarcopenia or frailty
comprising administering vitamin B12 to a subject in need thereof.
In a further aspect the present invention provides the use of vitamin B12 as
described herein
for the manufacture of a medicament for:
(a) maintaining or increasing muscle function and/or mass in an ageing
subject;
(b) substantially preventing or reducing muscle wasting in an ageing
subject;
and/or
(c) treating sarcopenia or frailty.
18
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Vitamin B12 deficiency
In one embodiment the subject may be vitamin B12 deficient.
The Recommended dietary allowance (RDA) of US adults was set at 2.4 pg per day
by the
Institute of Medicine, based on an average absorption from food of ¨50%
(National Academy
of Sciences, Institute of Medicine (2000); Dietary Reference Intakes for
Thiamin, Riboflavin,
Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline,
Chapter 9,
pp306-56). It was noted that the daily requirement varies with body size.
The likelihood of vitamin B12 deficiency in humans may be defined according to
the serum
vitamin B12 level as follows: <148 picomols/L (<200 picograms/mL) indicates
probable
deficiency, 148 to 258 picomols/L (201 to 350 picograms/mL) indicates possible
deficiency
and >258 picomols/L (>350 picograms/mL) indicates that deficiency is unlikely
(BMJ, Best
Practice, http://bestpractice.bmj.com/best-
practice/monograph/822/basics.html). However,
because of the lack of a gold standard for determining vitamin B12 levels and
related
complications regarding active and inactive vitamin B12, assays of serum
vitamin B12 are
often combined with further biochemical assays or clinical assessment based on
presenting
symptoms, in order to diagnose vitamin B12 deficiency.
Additional assays which may be performed to give a further indication of a
vitamin B12
deficiency include determining the level of, holotranscobalamine,
methylmalonic acid and/or
homocysteine in a sample isolated from the subject.
Holotranscobalamin refers to vitamin B12 bound to its bioactive serum
transporter
transcobalamine II. Holotranscobalamin levels may be determined using
commercial
available assays (e.g. ELISA assays). Low levels of holotranscobalamin are
associated with
a potential vitamin B12 deficiency.
Methyl-malonic acid (MMA) accumulates with low activity of the vitamin B12-
dependent
enzyme methylmalonylCoA mutase. As such high levels of MMA are associated with
vitamin
B12 deficiency.
Homocysteine accumulates with low activity of the vitamin B12-dependent enzyme
methionine
synthase. Low High levels of homocysteine are associated with vitamin B12
deficiency.
However assays of homocysteine levels can be confounded by folate deficiency.
Vitamin B12 may, for example, be provided in the form of a tablet, liquid
(e.g. for ingestion, or
use in a nasal spray or injection) or transdermal patch. For example, vitamin
B12 is available
as a nutritional supplement either on its own or in combination with other
supplements.
19
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Oral supplementation typically involves giving 250 pg to 1 mg of vitamin B12
daily.
The present invention may comprise administering a probiotic supplement
comprising vitamin
B12 producing bacteria to a subject.
The probiotic supplement can include any probiotic microorganism(s) which
beneficially affect
the host subject by improving its intestinal microbial balance to enhance
vitamin B12 uptake.
The probiotic microorganism can be selected from the group comprising of
Bifidobacterium,
Lactobacillus, Streptococcus, Enterococcus and Saccharomyces or mixtures
thereof.
Certain probiotic microorganisms which are native components of the gut
microbiota are
known to produce vitamin B12, for example, lactic acid producing bacteria such
as
Lactobacillus. delbrueckiisubsp. bulgaricus (see Le Blanc et al.; J App.
Micro.; 111(6); (2011)).
Advantageously, the probiotic supplement can enhance existing microorganisms
in the gut
that produce vitamin B12 in situ.
The oral vitamin B12 supplementation may be in the form of a food or beverage
product. The
food or beverage product may comprise a probiotic supplement comprising
vitamin B12
producing bacteria or other probiotics which can enhange existing
microorganisms in the gut
that produce vitamin B12 in situ.
Typically, a physician will determine the actual dosage which will be most
suitable for an
individual subject and it will vary with the age, weight and response of the
particular patient.
The dosage is such that it is sufficient to provide required levels of active
vitamin B12.
In one aspect, the invention provides a combined preparation of neuregulin-1
(NRG1) or a
fragment thereof of the invention and vitamin B12, wherein the NRG1 or
fragment thereof and
vitamin B12 are for simultaneous, combined, sequential or separate
administration to a
subject.
By "simultaneous", it is to be understood that the two agents are administered
concurrently,
whereas the term "combined" is used to mean they are administered, if not
simultaneously,
then "sequentially" within a time frame that they both are available to act
therapeutically within
the same time frame. Thus, administration "sequentially" may permit one agent
to be
administered within 5 minutes, 10 minutes or a matter of hours after the other
provided the
circulatory half-life of the first administered agent is such that they are
both concurrently
present in therapeutically effective amounts. The time delay between
administration of the
components will vary depending on the exact nature of the components, the
interaction there-
between, and their respective half-lives.
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
In contrast to "combined" or "sequential", "separate" is to be understood as
meaning that the
gap between administering one agent and the other agent is significant, i.e.
the first
administered agent may no longer be present in the bloodstream in a
therapeutically effective
amount when the second agent is administered.
Muscle function and mass
The compounds, compositions, uses and methods of the invention may provide for
the
maintenance of or increase in muscle function and/or mass in an ageing
subject.
The term "muscle function" refers to the ability of a muscle to perform in a
manner that does
not negatively impact on the life of a subject, and encompasses parameters of
muscle
strength, muscle contraction, muscle endurance and/or muscle elasticity.
Suitable tests for assessing muscle function include grip strength assessment
using a
dynamometer; one repeat maximum on leg press, chest press or leg extension;
gait speed; 6
min walk test; time up and go; short physical performance battery; Fried
frailty criteria; and
stair climbing time assessments.
Muscle mass (which may equate with muscle volume, muscle thickness or
myofiber/muscle
fiber size) may be measured by dual-energy X-ray absorptiometry (DXA) or
bioimpedance
tests. Similarly, MRI may be used for assessing muscle volume and ultra-sound
may be used
for assessing muscle thickness and pennation angle.
Preferably, the compounds, compositions, uses and methods of the invention
provide for the
maintenance of or increase in muscle mass in an ageing subject
The term "maintains" refers to a particular parameter, such as muscle function
and/or mass,
remaining substantially unchanged over a period of time (e.g. 5, 10, 15, 20,
25, 30, 40, 50 or
more years).
In one embodiment, muscle mass increases by at least 1%, 2%, 3%, 4%, 5%, 10%,
15% or
20%.
In another embodiment, muscle mass increases by 1-2.5%, 1-5%, 1-10% or 1-20%.
Preferably, the muscle is skeletal muscle.
Method of treatment
21
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
It is to be appreciated that all references herein to treatment include
curative, palliative and
prophylactic treatment; although in the context of the invention references to
preventing are
more commonly associated with prophylactic treatment. Treatment may also
include arresting
progression in the severity of a disease.
Subject
The treatment of mammals, particularly humans, is preferred. However, both
human and
veterinary treatments are within the scope of the invention.
The ageing subjects to be treated may, for example, be a human subject over
the age of 30,
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 years old. For
veterinary applications,
the age of the animal would be scaled from the human situation using the
average lifespan for
calibration.
In embodiments of the present invention the NRG1 or a fragment thereof or the
vitamin B12
is administered to an ageing subject as a medicament in order to maintain or
increase muscle
function, and/or substantially prevent or reduce muscle wasting, and/or to
treat sarcopenia or
frailty, wherein the subject has reduced muscle mass and/or muscle function
which causes
debilitation and/or a negative impact on the subject's quality of life.
Sarcopenia and frailty
The invention provides a means to address loss of muscle function and mass
that occurs with
age. Age-related loss of muscle function and mass occurs inevitably in all
individuals, however
its progression depends on a range of genetic and environmental factors, such
as physical
activity and nutritional intake.
The specific condition of sarcopenia is defined as occurring at the point at
which the age-
related loss of muscle mass and function becomes debilitating and impacts on
quality of life
(Sayer, A.A. et al. (2013) Age Ageing 42:145-150). In contrast, frailty is a
classification of age-
related muscle dysfunction which relies on muscle strength and functionality,
but not muscle
mass (Morley, J.E. et al. (2013) J. Am. Med. Dir. Assoc. 14: 392-397).
Sarcopenia and frailty are multi-factorial syndromes which associate with
pathophysiological
changes, such as impaired neuro-muscular transition, altered
excitation/contraction coupling,
impaired regenerative capacity linked to stem cell exhaustion, defects of
mitochondria! and
energy metabolism in myofibers, and marbling of skeletal muscle with fat and
fibrosis (Ali, S.
et al. (2014) Gerontology 60: 294-305). The aetiology of these syndromes is
therefore complex
and poorly understood, but low physical activity, hormonal decline in anabolic
hormones (e.g.
22
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
androgens and IGF-1), and malnutrition and/or nutritional deficiencies play an
important role
(Mithal, A. et al. (2013) Osteoporos. Int. 24: 1555-1566).
Method of screening
In one aspect, the invention provides a method of screening for an agent
capable of increasing
neuregulin-1 (NRG1) levels in a subject. The method may comprise the steps:
(a) contacting a population of cells with a candidate agent;
(b) determining the level of NRG1 in the population of cells; and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level in
a
control population of cells which has not been contacted with the candidate
agent.
Preferably, the method is an in vitro method.
The candidate agent may, for example be a pharmaceutical agent or nutritional
supplement.
Preferably, the candidate agent is a nutritional supplement.
In one embodiment, the candidate agent is comprised in a library of candidate
agents.
In one embodiment, the population of cells is a population of nerve (e.g.
nerve Schwann cells,
in particular rat primary cells) or muscle cells (e.g. the 02012 cell line
and/or human primary
myoblasts). In another embodiment, the population of cells is a combined
population of nerve
and muscle cells.
The term "level of NRG1" refers to the amount of NRG1 protein that is found in
a sample. The
amount of NRG1 protein may be determined directly or indirectly. Direct
methods of
determining NRG1 include SDS-PAGE, Western blotting, chromatographic methods
(e.g.
HPLC or FPLC), mass spectrometry-based methods (e.g. LC/MS) and NMR. Indirect
methods
of determining NRG1 include methods based on the detection of NRG1-encoding
nucleic
acids, in particular mRNAs, such as qPCR.
The effect of the candidate agent on NRG1 levels may be assessed as a function
of time, by
carrying out repeated measurements over a particular time-course.
Candidate agents may also be analysed (e.g. as a validation in a subsequent
step of the
screening method) for their effect on myelination in a Schwann cell/motor
neuron co-culture
system.
23
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Example screening methods include:
(a) Muscle cell-based screen (e.g. 02012 cell line and/or human primary
myoblasts): Cells may be grown to 90% confluence and induced to
differentiate for up to 14 days. Candidate agents may be added to the
medium for 1-2 days and NRG1 expression may be evaluated by qPCR.
(b) Nerve Schwann cell-based screen (rat primary cells). Cells may be grown
in proliferating conditions and candidate agents may be added to the
medium for 1-2 days. NRG1 expression may be evaluated by qPCR.
(c) Candidate agents may also be tested in a co-culture system (Schwann
cells/motor neurons) to evaluate myelination.
Example candidate agents may include lipoic acid, vitamin B12 derivatives,
HDAC inhibitors
and/or traditional Chinese medicine components.
Method of diagnosis
In one aspect, the invention provides a method of diagnosing sarcopenia or
frailty comprising
the steps:
(a) providing a biological sample isolated from a subject;
(b) determining the level of neuregulin-1 (NRG1) in the biological sample;
and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level
determined from one or more control samples or reference levels.
The one or more control samples may be isolated from a subject with or without
sarcopenia
or frailty. Accordingly, comparison with such control samples may provide an
indication of the
subject having sarcopenia or frailty, or deteriorating towards the state of
sarcopenia or frailty.
Alternatively or additionally, a level of NRG1 below a pre-determined
reference level may
indicate the subject has sarcopenia or frailty, while a level of NRG1 above a
different pre-
determined reference level may indicate the subject does not have sarcopenia
or frailty.
The term "level of NRG1" refers to the amount of NRG1 protein that is found in
a sample. The
amount of NRG1 protein may be determined directly or indirectly. Direct
methods of
determining NRG1 include SDS-PAGE, Western blotting, chromatographic methods
(e.g.
HPLC or FPLC), mass spectrometry-based methods (e.g. LC/MS) and NMR. Indirect
methods
24
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
of determining NRG1 include methods based on the detection of NRG1-encoding
nucleic
acids, in particular mRNAs, such as qPCR.
The biological sample may be any suitable sample for isolating from the body
of a subject,
such as a blood sample (e.g. plasma or serum) or tissue biopsy (in particular
a muscle biopsy).
In one embodiment, the method may comprise a further step of administering the
NRG1 or
fragment thereof of the invention to the subject, wherein the subject has been
diagnosed as
having sarcopenia or at being risk of developing sarcopenia, or diagnosed as
being frail or at
being risk of becoming frail.
In another embodiment, the method may comprise a further step of applying a
dietary
intervention for maintaining or increasing muscle function and/or mass wherein
the subject
has been diagnosed as having sarcopenia or being at risk of developing
sarcopenia, or
diagnosed as being frail or at being risk of becoming frail. Preferably, the
dietary intervention
is for maintaining or increasing muscle mass. Example dietary interventions
include high
protein and/or carbohydrate diets.
In another aspect, the invention provides a method of diagnosing loss of
muscle function
and/or mass with age comprising the steps:
(a) providing a biological sample isolated from a subject;
(b) determining the level of neuregulin-1 (NRG1) in the biological sample;
and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level
determined from one or more control samples or reference levels.
The loss of muscle function and/or mass may be associated with sarcopenia or
frailty.
In another aspect, the invention provides a method of selecting a dietary
intervention
comprising the steps:
(a) providing a biological sample isolated from a subject;
(b) determining the level of neuregulin-1 (NRG1) in the biological sample;
(c) comparing the level of NRG1 determined in step (b) with a
NRG1 level
determined from one or more control samples or reference levels; and
(d) applying a dietary intervention for maintaining or increasing muscle
function
and/or mass wherein the subject has been diagnosed as having sarcopenia
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
or being at risk of developing sarcopenia, or diagnosed as being frail or at
being risk of becoming frail.
Preferably, the dietary intervention is for maintaining or increasing muscle
mass. Example
dietary interventions include high protein and/or carbohydrate diets, and
vitamin B12 and/or
vitamin D supplements.
A control sample may be from the same subject, taken at an earlier time point.
Similarly, a
reference level may be determined based on previous analyses carried out on
the same
subject. Accordingly in another aspect, the invention provides a method of
determining the
progression of sarcopenia or frailty in a subject comprising the steps:
(a) providing a biological sample isolated from a subject;
(b) determining the level of neuregulin-1 (NRG1) in the biological sample;
and
(c) comparing the level of NRG1 determined in step (b) with a NRG1 level
determined from a sample taken from the same subject at an earlier time.
Dietary intervention and product
The term "dietary intervention" refers to an external factor applied to a
subject which causes
a change in the subject's diet. In one embodiment, the dietary intervention is
a high calorie
diet. In another embodiment, the dietary intervention is a high protein and/or
carbohydrate
diet. In another embodiment, the dietary intervention is a diet supplemented
with vitamins and
minerals, in particular vitamin B12 and/or vitamin D.
In a preferred embodiment, the dietary intervention is a diet supplemented
with vitamin B12,
in particular adenosylcobalamin and/or methylcobalamin.
In another preferred embodiment, the dietary intervention is a diet
supplemented with vitamin
B12, in particular hydroxocobalamin and/or cyanocobalamin which can be
converted into
methylcobalamin and/or adenosylcobalamin.
The diet may be one which is adjusted to the starting body weight of the
subject.
The dietary intervention may comprise administration of at least one diet
product. The diet
product may be a meal replacement product or a supplement product which may,
for example,
increase the subject's appetite. The diet product may include food products,
drinks, pet food
products, food supplements, nutraceuticals, food additives or nutritional
formulas. Example
oral nutritional supplements include Nestle Boost and Meritene products.
26
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Variants, derivatives, analogues, homologues and fragments
In addition to the specific proteins and nucleotides mentioned herein, the
invention also
encompasses the use of variants, derivatives, analogues, homologues and
fragments thereof.
In the context of the invention, a variant of any given sequence is a sequence
in which the
specific sequence of residues (whether amino acid or nucleic acid residues)
has been modified
in such a manner that the polypeptide or polynucleotide in question
substantially retains its
function. A variant sequence can be obtained by addition, deletion,
substitution, modification,
replacement and/or variation of at least one residue present in the naturally-
occurring protein.
The term "derivative" as used herein, in relation to proteins or polypeptides
of the invention
includes any substitution of, variation of, modification of, replacement of,
deletion of and/or
addition of one (or more) amino acid residues from or to the sequence
providing that the
resultant protein or polypeptide substantially retains at least one of its
endogenous functions.
The term "analogue" as used herein, in relation to polypeptides or
polynucleotides includes
any mimetic, that is, a chemical compound that possesses at least one of the
endogenous
functions of the polypeptides or polynucleotides which it mimics.
Typically, amino acid substitutions may be made, for example from 1, 2 or 3 to
10 or 20
substitutions provided that the modified sequence substantially retains the
required activity or
ability. Amino acid substitutions may include the use of non-naturally
occurring analogues.
Proteins used in the invention may also have deletions, insertions or
substitutions of amino
acid residues which produce a silent change and result in a functionally
equivalent protein.
Deliberate amino acid substitutions may be made on the basis of similarity in
polarity, charge,
solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of
the residues as long
as the endogenous function is retained. For example, negatively charged amino
acids include
aspartic acid and glutamic acid; positively charged amino acids include lysine
and arginine;
and amino acids with uncharged polar head groups having similar hydrophilicity
values include
asparagine, glutamine, serine, threonine and tyrosine.
Conservative substitutions may be made, for example according to the table
below. Amino
acids in the same block in the second column and preferably in the same line
in the third
column may be substituted for each other:
27
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
ALIPHATIC Non-polar G A P
ILV
Polar - uncharged CSTM
NQ
Polar - charged D E
K R H
AROMATIC F W Y
The term "homologue" as used herein means an entity having a certain homology
with the
wild type amino acid sequence and the wild type nucleotide sequence. The term
"homology"
can be equated with "identity".
A homologous sequence may include an amino acid sequence which may be at least
50%,
55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% identical, preferably at least 95% or
97% or
99% identical to the subject sequence. Typically, the homologues will comprise
the same
active sites etc. as the subject amino acid sequence. Although homology can
also be
considered in terms of similarity (i.e. amino acid residues having similar
chemical
properties/functions), in the context of the invention it is preferred to
express homology in
terms of sequence identity.
A homologous sequence may include a nucleotide sequence which may be at least
50%, 55%,
60%, 65%, 70%, 75%, 80%, 85% or 90% identical, preferably at least 95% or 97%
or 99%
identical to the subject sequence. Although homology can also be considered in
terms of
similarity, in the context of the invention it is preferred to express
homology in terms of
sequence identity.
Preferably, reference to a sequence which has a percent identity to any one of
the SEQ ID
NOs detailed herein refers to a sequence which has the stated percent identity
over the entire
length of the SEQ ID NO referred to.
Homology comparisons can be conducted by eye or, more usually, with the aid of
readily
available sequence comparison programs. These commercially available computer
programs
can calculate percentage homology or identity between two or more sequences.
Percentage homology may be calculated over contiguous sequences, i.e. one
sequence is
aligned with the other sequence and each amino acid in one sequence is
directly compared
with the corresponding amino acid in the other sequence, one residue at a
time. This is called
an "ungapped" alignment. Typically, such ungapped alignments are performed
only over a
relatively short number of residues.
28
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Although this is a very simple and consistent method, it fails to take into
consideration that, for
example, in an otherwise identical pair of sequences, one insertion or
deletion in the nucleotide
sequence may cause the following codons to be put out of alignment, thus
potentially resulting
in a large reduction in percent homology when a global alignment is performed.
Consequently,
most sequence comparison methods are designed to produce optimal alignments
that take
into consideration possible insertions and deletions without penalising unduly
the overall
homology score. This is achieved by inserting "gaps" in the sequence alignment
to try to
maximise local homology.
However, these more complex methods assign "gap penalties" to each gap that
occurs in the
alignment so that, for the same number of identical amino acids, a sequence
alignment with
as few gaps as possible, reflecting higher relatedness between the two
compared sequences,
will achieve a higher score than one with many gaps. "Affine gap costs" are
typically used that
charge a relatively high cost for the existence of a gap and a smaller penalty
for each
subsequent residue in the gap. This is the most commonly used gap scoring
system. High gap
penalties will of course produce optimised alignments with fewer gaps. Most
alignment
programs allow the gap penalties to be modified. However, it is preferred to
use the default
values when using such software for sequence comparisons. For example when
using the
GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences
is -12 for a
gap and -4 for each extension.
Calculation of maximum percentage homology therefore firstly requires the
production of an
optimal alignment, taking into consideration gap penalties. A suitable
computer program for
carrying out such an alignment is the GCG Wisconsin Bestfit package
(University of
Wisconsin, U.S.A.; Devereux et al. (1984) Nucleic Acids Res. 12: 387).
Examples of other
software that can perform sequence comparisons include, but are not limited
to, the BLAST
package (see Ausubel et al. (1999) ibid ¨ Ch. 18), FASTA (Atschul et al.
(1990) J. Mol. Biol.
403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are
available for offline and online searching (see Ausubel et al. (1999) ibid,
pages 7-58 to 7-60).
However, for some applications, it is preferred to use the GCG Bestfit
program. Another tool,
called BLAST 2 Sequences is also available for comparing protein and
nucleotide sequences
(see FEMS Microbiol. Lett. (1999) 174: 247-50; FEMS Microbiol. Lett. (1999)
177: 187-8).
Although the final percent homology can be measured in terms of identity, the
alignment
process itself is typically not based on an all-or-nothing pair comparison.
Instead, a scaled
similarity score matrix is generally used that assigns scores to each pairwise
comparison
based on chemical similarity or evolutionary distance. An example of such a
matrix commonly
used is the BLOSUM62 matrix ¨ the default matrix for the BLAST suite of
programs. GCG
29
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
Wisconsin programs generally use either the public default values or a custom
symbol
comparison table if supplied (see the user manual for further details). For
some applications,
it is preferred to use the public default values for the GCG package, or in
the case of other
software, the default matrix, such as BLOSUM62.
Once the software has produced an optimal alignment, it is possible to
calculate
percent homology, preferably percent sequence identity. The software typically
does this as
part of the sequence comparison and generates a numerical result.
"Fragments" of neuregulin-1 (NRG1) are also variants and the term typically
refers to a
selected region of the polypeptide or polynucleotide that is of interest
either functionally or, for
example, in an assay. "Fragment" thus refers to an amino acid or nucleic acid
sequence that
is a portion of a full-length polypeptide or polynucleotide.
Such variants may be prepared using standard recombinant DNA techniques such
as site-
directed mutagenesis. Where insertions are to be made, synthetic DNA encoding
the insertion
together with 5' and 3' flanking regions corresponding to the naturally-
occurring sequence
either side of the insertion site may be made. The flanking regions will
contain convenient
restriction sites corresponding to sites in the naturally-occurring sequence
so that the
sequence may be cut with the appropriate enzyme(s) and the synthetic DNA
ligated into the
cut. The DNA is then expressed in accordance with the invention to make the
encoded protein.
These methods are only illustrative of the numerous standard techniques known
in the art for
manipulation of DNA sequences and other known techniques may also be used.
EXAMPLES
Example 1
Materials and methods
Variation of circulating levels of neuregulin-1 (NRG1) with age in rats.
Neuregulin-1 (NRG1, in particular the NRG1 beta EGF domain) levels were
measured in
serum from rats aged 8 months, 18 months or 24 months using slow off-rate DNA
aptamer
detection (Gold, L. et al. (2010) PLoS ONE 5: e15004). 10 animals per group
were analysed.
Effect of neuregulin-1 (NRG1) on neuromuscular junctions in vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (2.5 pM) and riluzole (5
pM) was
used as a positive control for preserving neuromuscular junctions from Ab-
induced damage.
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
The effect of neuregulin-1 (NRG1; various concentrations, as specified in
Figure 2) on Ab-
induced damage was evaluated by measuring the neuromuscular junction (NMJ)
size. 6 wells
per group were analysed and compared to a control condition. The uninjured
control condition
is the neuromuscular junction size without Ab treatment. All other conditions
are to be
compared to the Ab treatment alone which represents the reference value for
damaged
neuromuscular junction size.
Effect of neuregulin-1 (NRG1) on age-induced atrophy of skeletal muscle.
Pre-sarcopenic rats aged 16 months were treated for 5 months with either
neuregulin-1
(NRG1; NRG1 beta EGF domain from Reprokine (catalog number RKQ02297)) or
saline.
NRG1 was injected sub-cutaneously at 1 pg/kg body weight 3 time per week. Hind-
limb
skeletal muscle mass was then evaluated and compared to a group of adult
healthy rats (8
months at start of experiment) injected with saline control. Hind-limb
skeletal muscle mass
was then evaluated and compared to an adult healthy group of rats.
Effect of vitamin B12 on neuromuscular junctions in vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (2.5 pM) and riluzole (5
pM) was
used as a positive control for preserving neuromuscular junctions from Ab-
induced damage.
The effect of methylcobalamin (MeCbl; 1 or 100 nM) and adenosylcobalamin
(AdenoCb1; 1 or
100 nM) on Ab-induced damage was evaluated by measuring the neuromuscular
junction
(NMJ) number and size, and the neurite network. 6 wells per group were
analysed and
compared to a control condition (CTL). The uninjured control condition is the
neuromuscular
junction size without Ab treatment. All other conditions are to be compared to
the Ab treatment
alone which represents the reference value for damaged neuromuscular junction
size.
Effect of vitamin B12 on skeletal muscle in vivo.
Pre-sarcopenic rats aged 16 months were treated for 5 months with either
adenosylcobalamin
(AdoCbl, 00884, Sigma aldrich), methylcobalamin (MeCbl, M9756, Sigma aldrich)
or saline.
AdoCbl and MeCbl were injected sub-cutaneously at 1mg/kg body weight 3 time
per week.
Tibialis Anterior (TA) was then dissected out and frozen for further analyses.
For histology, TA
was cryo-sectioned at 10pm and stained with laminin (L9393, Sigma aldrich) to
delineate
fibers. Specific fiber types 1, 2A and 2B were immunolabeled subsequently with
appropriate
antibodies (clones BAD5, BFF3, and S071 respectively, DSHB). Images were
acquired using
a slide scanner (VS-120, Olympus) and analyzed using an in-house MetaXpress
journal
(Molecular Devices, Sunnyvale, USA). Images from old animals were compared to
a group of
31
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
adult healthy rats (8 months at start of experiment) injected with saline
control. For gene
expression analysis, total RNA was extracted using the miRNeasy Mini Kit
(Qiagen) according
to the manufacturer's instruction and RNA quality was checked using the
Standard Sensitivity
RNA Analysis Kit on a Fragment Analyzer (Advanced Analytical Technologies).
Samples were
then hybridized on Affymetrix Rat 230 PM 96-Array following standard
Affymetrix protocol,
based on the Eberwine T7 procedure. Statistical analysis was performed using
LIMMA and
exploited in GSEA to compare old control animals versus adult animals, and old
animals
treated with either AdoCbl or MeCbl versus old control animals.
Effect of vitamin B12 on protection from muscle atrophy
HSMM human myoblasts were grown in vitro and induced to differentiate into
mature
myotubes. Myotube atrophy was induced by incubation with TNFa at 4Ong/m1 for 4
days.
MeCbl (1M) and AdoCbl (1M) were incubated together with TNFa to test their
effect on
induced atrophy. IGF1 is used as a positive control at 15nM to prevent muscle
atrophy. After
4 days of treatment, cells were stained for nuclei and myosin heavy chain to
quantify the
proportion of nuclei inside myotubes (i.e fusion index).
Effect of neuregulin-1 (NRG1) and vitamin B12 on neuromuscular junctions in
vitro.
Nerve and muscle co-cultures were grown in vitro until neuromuscular junctions
were mature.
Damage was induced using beta-amyloid (Ab) incubation (10 pM) and riluzole (5
pM) was
used as a positive control for preserving neuromuscular junctions from Ab-
induced damage.
The effect of neuregulin-1 (NRG1; 30 nM) and/or adenosylcobalamin (AdoCbl; 1
nM) on Ab-
induced damage was evaluated by measuring the neuromuscular junction (NMJ)
size or
number. 6 wells per group were analysed and compared to a control condition
(CTL) without
Ab-induced damage.
Results
Using an aptamer-based screen (Somalogic) on serum from rats aged 8 months, 18
months
or 24 months, we found that neuregulin-1 (NRG1) circulating levels decrease
with age (Figure
1). This decrease is concomitant with the progression of sarcopenia.
Considering that neuregulin-1 plays major roles both at the nerve and the
neuromuscular
junction levels, we then sought to investigate whether neuregulin-1 could
protect the
neuromuscular junction from the damage that occurs during ageing. For this
purpose, we used
an in vitro co-culture model that allows the formation and maintenance of
neuromuscular
junctions, and we induced damage with b-amyloid incubation.
32
CA 03008925 2018-06-18
WO 2017/108419
PCT/EP2016/080182
As shown in Figure 2, neuregulin-1 was able to protect the neuromuscular
system from
damage at a dose of 30 nM. Collectively these results suggest that neuregulin-
1 is beneficial
for the maintenance of the neuromuscular system, and that the loss of this
protein with age
may be linked with the progression of sarcopenia.
To test whether a neuregulin-1 treatment could rescue the sarcopenia
phenotype, we treated
pre-sarcopenic rats for 5 months with neuregulin-1 and evaluated their
skeletal muscle mass
as compared with adult rats and pre-sarcopenic rats treated with saline as
control.
As shown in Figure 3, we observed that hindlimb muscles from rats treated with
neuregulin-1
have a significantly higher mass compared to controls, demonstrating that
neuregulin-1 has
prevented the age-induced skeletal muscle atrophy.
Taken together, our results suggest that neuregulin-1 protects the
neuromuscular system from
age-related dysfunction and could therefore be used to prevent sarcopenia.
Given the previously reported actions of vitamin B12 on neurons and the
nervous system, we
also tested the effect of the 2 active forms of vitamin B12 (methylcobalamin
and
adenosylcobalamin). Adenosylcobalamin, but not methylcobalamin, was also able
to protect
the system at both doses tested (Figure 4).
Interestingly when the system was subjected to a stronger damage (longer
incubation of beta-
amyloid at a higher concentration), neither neuregulin-1 nor adenosylcobalamin
alone could
rescue the system but a co-treatment provided a mild protection suggesting
that the two may
have synergic effects (Figure 5).
As shown in Figure 6, adenosylcobalamin, but not methylcobalamin, was also
able to induce
an increase in muscle fiber size in aged rats.
In contrast, methylcobalamin was able to protect from muscle atrophy (Figure
7).
This differential effect may be caused by the fact that adenosylcobalamin and
methylcobalamin rescue different age-related gene expression signatures in
skeletal muscle
(Figure 8).
All publications mentioned in the above specification are herein incorporated
by reference.
Various modifications and variations of the described compounds, compositions,
uses and
methods of the present invention will be apparent to those skilled in the art
without departing
from the scope and spirit of the present invention. Although the present
invention has been
described in connection with specific preferred embodiments, it should be
understood that the
33
CA 03008925 2018-06-18
WO 2017/108419 PCT/EP2016/080182
invention as claimed should not be unduly limited to such specific
embodiments. Indeed,
various modifications of the described modes for carrying out the invention,
which are obvious
to those skilled in biochemistry and biotechnology or related fields, are
intended to be within
the scope of the following claims.
34
